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Abstract 
 
In this work novel magnetic cationic liposomal nanoformulations were synthesized for the 
encapsulation of a crystallographically defined ternary V(IV)-curcumin-bipyridine (VCur) complex 
with proven bioactivity, as potential anticancer agents. The liposomal vesicles were produced via the 
thin film hydration method employing N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium 
(DOTAP) and egg phosphatidylcholine lipids and were magnetized through the addition of citric acid 
surface-modified monodispersed magnetite colloidal magnetic nanoparticles. The obtained 
nanoformulations were evaluated for their structural and textural properties and shown to have 
exceptional stability and enhanced solubility in physiological media, demonstrated by the 
entrapment efficiency and loading capacity results and the in vitro release studies of their cargo. 
Furthermore, the generated liposomal formulations preserved the superparamagnetic behavior of 
the employed magnetic core maintaining the physicochemical and morphological requirements for 
targeted drug delivery applications. The novel nanomaterials were further biologically evaluated for 
their DNA interaction potential and were found to act as intercalators. The findings suggest that the 
positively charged magnetic liposomal nanoformulations can generate increased concentration of 
their cargo at the DNA site, offering a further dimension in the importance of cationic liposomes as 
nanocarriers of hydrophobic anticancer metal ion complexes for the development of new 
multifunctional pharmaceutical nanomaterials with enhanced bioavailability and targeted antitumor 
activity. 
 
1. Introduction 
Given the limitations of currently available chemotherapeutic approaches [1], magnetic drug 
targeting represents an innovative strategy that facilitates selective delivery and retention of various 
therapeutic agents at specific tissues [2–7]. In this approach, the prospective curative agents, bound 
to magnetic nanoparticles (MNPs) (ferrofluids) capable of responding to external magnetic fields, are 
effectively carried into the microcirculation of the tumor, thus minimizing drug accumulation in 
healthy peripheral tissues [8,9]. Among various types of nanoparticles (NPs), biocompatible 
superparamagnetic iron oxide (SPIO) NPs, with proper surface architecture, have attracted extensive 
attention, both for cellular imaging and drug delivery biomedical applications [10–14], due to their 
physical properties and biocompatible nature [15]. MNPs for biomedical applications should be 
hydrophilic and stable in water. Aqueous colloidal dispersions of MNPs hold great merit for use in 
diagnosis and treatment of diseases due to the: a) compatibility of the aqueous medium with the 
biosystem, b) controllable size distribution, c) uniform shape, d) strong magnetic susceptibility, e) 
directability induced by applied magnetic force, and f) capacity for surface functionalization with 
specific compounds and/or biomolecules [16–19]. 
 
One class of NPs with distinct advantages in drug delivery is liposomes (LPs). LPs are hollow colloidal 
microspheres, formed by curved bilayered membranes of self-aggregated lipids. LPs can entrap part 
of the aqueous medium in which they are suspended [20]. The amphiphilic character of lipids and 
their dense structural organization enable LPs to encapsulate hydrophobic compounds in the bilayer 
membrane and/or hydrophilic molecules in the internal aqueous cavity, as well as amphiphilic 
substances whose hydrophobic part anchors in the lipid bilayer and the polar part remains in the 
membrane polar region or in the internal aqueous phase [21]. Lately, MNPs have been combined 
with LPs in the development of integrated systems termed magnetic LPs or magnetoliposomes 
(MLPs) with remarkable potentials as fluorescent and imaging contrast agents or hyperthermia 
inducing agents [22,23]. 
 
A more recent contribution to the field of targeted drug delivery involves the use of cationic LPs 
(CLPs) [24–27]. CLPs are generally employed as gene delivery systems due to their low 
immunogenicity and toxicity, size-independent delivery of nucleic acids, quality control, and ease of 
preparation [28]. CLPs, unlike their electroneutral and anionic counterparts, possess a fivefold 
enhanced targeted selectivity in tumor vessels over normal vessels in healthy tissues [29]. However, 
despite their preferential accumulation in tumors, they attain non-uniform distribution along tumor 
vessels. The combination of the electrostatic properties of CLPs with the application of magnetic 
drug targeting through the employment of MNPs can result in the formation of tumor specific 
delivery vehicles that can interact uniformly with the tumor vasculature and respond to an externally 
applied magnetic field [30]. 
 
Curcumin constitutes an excellent natural product for cancer treatment, however, its low aqueous 
solubility along with its rapid metabolism, poor absorption, and systemic elimination limit its 
bioavailability [31]. Curcumin-based metal complexes, not only help overcome the limited 
bioavailability of curcumin, but also exhibit significant biological activity demonstrating in many 
cases enhanced antitumor potential [32]. More specifically, oxovanadium(IV) complexes of curcumin 
with enhanced photocytotoxicity have been used as photosensitizers in PDT (photodynamic 
therapy), selectively activated at the photo-exposed cancer site in order to generate reactive oxygen 
species (ROS) [33–35]. 
In the present work, the third crystallographically reported oxovanadium(IV) complex of curcumin 
(VCur) (Fig. 1) with significant anti-ROS/anti-oxidant activity and DNA degradation potential [36] is 
encapsulated for the first time in magnetic cationic liposomal nanocarriers in the effort to create 
novel nanoformulations with targeted anticancer activity based on metal complexes of bioactive 
natural polyphenols. 
 
In recent years, various studies have shown that incorporation of curcumin into LPs increases 
significantly its aqueous solubility and ameliorates its pharmacokinetic and bioavailability limitations. 
Liposomal curcumin has been reported to exhibit higher stability than free curcumin in phosphate 
buffered saline (PBS), human blood, plasma and cell culture media [37]. Moreover, curcumin-loaded 
LPs have been shown to induce apoptosis and suppress tumor proliferation and angiogenesis of 
several cancer cell lines by downregulating the nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-κB), and many anti-apoptosis proteins including B-cell lymphoma 2 (Bcl2), B-cell 
lymphoma-extra large (BclXL), and cyclooxygenase-2 (COX-2) [38,39]. 
 
In the present study, the N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium (DOTAP) lipid will 
be employed in combination with egg L-α-phosphatidylcholine (EPC) (Fig. 2) to form the CLPs. The 
combination of these lipids is known to produce liposomal structures that display high cellular 
uptake and retain the molecular integrity of their liposomal membranes under physiological 
conditions [40]. 
 
To the best of our knowledge, only one application of DOTAP-derived CLPs as nanocarriers of metal 
complexes has been reported in the literature. More specifically, CLPs were shown to be efficient 
nanocarriers for the transport of anticancer ruthenium complexes in cells significantly enhancing 
their stabilization in aqueous media, transport in cells, and anticancer activity [41–45]. Their 
successful but unique application indicates the necessity for the pursuit of further research on the 
generation of stable and long-life magnetic liposomal nanocarriers for the targeted delivery of 
metal-based anticancer drugs [41]. 
 
With the hope that investigation of the homogeneous dispersion and encapsulation of hydrophobic 
anticancer metal ion complexes in magnetic cationic liposomes (MCLPs) will enable development of 
new multifunctional pharmaceutical nanomaterials with enhanced bioavailability and targeted 
antitumor activity, this work for the first time a) evaluates and compares the anticancer efficiency 
and DNA-binding capacity of a crystallographically defined ternary V(IV)-curcumin-bipyridine 
complex (VCur) with proven bioactive efficacy [36] (Fig. 1), b) leads to the synthesis of citric acid (CA) 
surface-modified monodispersed magnetite (Fe3O4-CA) colloidal magnetic NPs (MNPs), c) develops 
MCLPs (mentioned henceforth as empty MCLPs, EMCLPs) via the thin film hydration method, d) 
evaluates and compares the suitability of these magnetic cationic liposomal vesicles as potential 
nanocarriers of VCur, (mentioned henceforth as VCur-loaded MCLPs, VCMCLPs), and e) investigates 
structural and textural properties of the encapsulated material through different and 
complementary characterization techniques. 
 
 
Fig. 1. Crystal structure of the V(IV)-curcumin-bipyridine complex (VCur) employed in this study.  
 
2. Materials and methods 
 
2.1. Materials 
 
The starting materials used include: Iron(II) chloride tetrahydrate  (FeCl2 .4H2O), iron(III) chloride 
hexahydrate (FeCl3.6H2O), ammonia solution (~25%), citric acid, curcumin, 2,2′-bipyridine, vanadyl 
sulphate trihydrate (VOSO4・3H2O), N-[1-(2,3-dioleoyloxy)propyl]-N,N,Ntrimethylammonium 
chloride (DOTAP chloride), egg L-α-phosphatidylcholine (EPC) (Type XI-E, 100 mg.ml-1 in chloroform, 
≥99%, solution), and PBS pH 7.4. These materials were purchased from commercial sources (Sigma, 
Fluka) and were used without further purification. 
 
Fig.2. Schematic representation of the lipids employed in this study for the formation of CLPs. 
 
Ultrapure water, chloroform, methanol (MeOH), ethanol (EtOH), and diethyl ether were used as 
solvents. Nitrogen gas was used for degassing ultrapure H2O and for maintaining a nitrogen 
atmosphere during the synthetic procedures, where applicable. Calf thymus DNA (CT-DNA) was 
obtained from Sigma Aldrich (USA) and used as received. All DNA experiments were performed in 
phosphate buffer (0.05 M, pH 7.2) prepared from Na2HPO4・7H2O and K2HPO4. The CT-DNA solution 
was sufficiently free of protein as evidenced by the ratio of its UV absorbance at 260 and 280 nm 
that was approx. 1.9:1 [46]. The DNA concentration per nucleotide was determined 
spectrophotometrically by using the molar absorption coefficient of ε=6600 M-1.cm-1 per nucleotide 
at 260 nm. Stock solutions of CT-DNA were stored at 4 °C and were used within 4 days. Before 
measurements, all compounds and DNA were incubated for 24 h at 25 °C to reach the equilibrium 
state. Before all DNA measurements, the mixtures of DNA-VCur or DNA-VCMCLPs were incubated 
for 24 h at 25 °C to reach the equilibrium state. Each reported measurement value is the average of 
three independent experiments. Experimental stock solutions of VCur were made in dimethyl 
sulfoxide (DMSO) at a concentration of 10-3 M, and stored in the dark at 0-4°C. Proper volumes 
from the VCur stock solution were added to achieve the desired ratios of R=[compound]/[DNA].  
 
The volumes required to reach the desired final concentrations of VCMCLPs in DNA solutions were 
determined based on the loading capacity of VCur in VCMCLPs (9.5%, see Section 3.11) and the 
release studies (Section 3.12). In all DNA studies, the effect of the presence of Fe3O4-CA NPs and 
EMCLPs, that served as control, were assessed at ratios R=0.01, 0.1 and 0.5. 
 
2.2. Characterization 
 
FT-Infrared spectra were recorded on a Perkin Elmer 1760X FT-infrared spectrometer. 
 
Crystal phase identification and relative percent composition in the synthesized materials were 
accomplished through X-ray diffraction (XRD) at ambient temperature on a Seifert XRD 3003-TT 
powder diffractometer using FeKα radiation in 2θ steps of 0.05o for 4 s. 
 
Magnetization measurements on Fe3O4-CA NP, EMCLP and VCMCLP dried powder samples were 
performed on a QD-Versalab VSM magnetometer, in fields up to 3 T and temperatures from 50 K to 
400 K. 
 
High resolution transmission electron microscopy (HRTEM) images of Fe3O4-CA NPs were acquired 
using a FEI Tecnai G2-F30 S-Twin microscope operated at 300 kV. Small amounts of Fe3O4-CA NPs 
dispersed in EtOH were drop-cast on holey carbon-coated copper grids and subsequently air-dried 
before TEM analysis. 
 
Transmission electron microscopy (TEM) images of EMCLPs and VCMCLPs were acquired using a 
Philips CM20 TEM, with particle size analysis performed manually with the assistance of ImageJ 
software. Samples were prepared for TEM analysis by sonicating the MCLPs in heptane, and 
pipetting a portion of the resulting mixture onto a holey carbon support film on 300 mesh copper 
TEM grid. This was allowed to dry in air, leaving a small amount of each sample on the grid ready for 
analysis. TEM images were obtained on a range of magnifications, using an accelerating voltage of 
200 kV. 
 
The surface chemistry of Fe3O4-CA NPs was investigated using a custom ultra-high vacuum X-ray 
photoelectron spectroscopy (XPS) system equipped with a 150mm mean radius hemispherical 
energy analyzer (Specs GmbH Phoibos 150) and a monochromatic AlKα X-ray source at 1486.6 eV 
(Specs GmbH Focus 500). The sample was prepared for XPS by drying onto clean Si(111) wafers, with 
data acquired as an area average over a region approximately 2mm in diameter. Survey scans were 
performed with a pass energy of 50 eV with scans over individual photoelectron lines performed at 
15 eV. Data were quantified using Scofield cross sections [47], corrected for energy dependencies of 
the analyzer transmission and the effective electron attenuation lengths. 
 
The morphology and detailed structural features of Fe3O4-CA NPs sample was investigated by 
scanning electron microscopy (SEM), using a high-resolution microscope FEI Quanta 3D FEG model, 
equipped with an energy dispersive X-ray (EDX) spectrometer Apollo X. The analyses were 
performed in high vacuum mode at different accelerating voltages (5-20 kV), with the pellets being 
analyzed directly (samples were immobilized on a double-sided carbon tape, without coating). The 
microstructure of EMCLPs and VCMCLPs was analyzed using a Zeiss Leo 1455VP SEM equipped with 
Oxford Instruments INCA X-Act EDX detector and operated at 20 kV. 
 
Mean particle size was determined through Dynamic Light Scattering (DLS) using Photon Correlation 
Spectroscopy (Malvern S4700 PCS System, Malvern Instruments Ltd, Malvern, UK). The analysis was 
performed at a scattering angle of 90o and at 25 °C, using samples appropriately dispersed in PBS 
(pH 7.4). For each sample, the mean diameter  standard deviation of six determinations was 
calculated applying multimodal analysis. Values reported are the mean diameter •} standard 
deviation for three replicate samples. 
 
Zeta-potential measurements of Fe3O4-CA NP, EMCLP, and VCMCLP samples were taken by Laser 
Doppler Anemometry (Malvern Zetasizer IV, Malvern Instruments Ltd, Malvern, UK). All analyses 
were performed on samples appropriately diluted with 1mM PBS buffer (adjusted to pH 7.4) in order 
to maintain constant ionic strength. The refractive index and viscosity of the medium were set at 
1.335 and 1.0200, respectively [48]. For each sample, the mean value standard deviation of four 
determinations was established. Values reported are the mean value standard deviation for two 
replicate samples.  
 
A Perkin Elmer, Pyris 1, system was used to run the simultaneous Thermogravimetric Analysis (TGA) 
experiments. The instrument mass precision is 1 μg. A specific amount (mg) of each sample was 
placed in an open alumina sample pan for each experiment. High purity air was used at a constant 
flow rate of 30 mL.min-1, depending on the conditions required for running the experiments. During 
the experiments, the sample weight loss and rate of weight loss were recorded continuously under 
dynamic conditions, as a function of time or temperature, in the range 30-850 °C. Prior to activating 
the heating routine program, the entire system was purged with the appropriate gas for 10 min, at a 
rate of 30 mL.min-1, to ensure that the desired environment had been established.  
 
Fe percentages were measured, after dissolving the samples in HCl, by flame atomic absorption 
spectrophotometry (FAAS) using a Perkin Elmer AAnalyst 800 instrument. 
 
The determination of entrapment efficiency and the in vitro release study of VCur were performed 
through High Performance Liquid Chromatography (HPLC) at a ThermoFinnigan Spectra HPLC system 
(San Jose, California) model UV 6000 LP, equipped with EZChromeElite software, Version 3.1.7., four 
Q-Grad pumps, a diode array detector (DAD) and a Grace Smart RP C-18 column (250×4.6mm id.; 5 
μm particle size). The injection volume was 20 μL and the wavelength used was 480 nm. The mobile 
phases were 1% (v/v) acetic acid in milli-Q H2O (eluent A) and 100% MeOH (eluent B) with a flow 
rate of 1 mL.min-1. The elution profile was as follows: from 0 min, 100% A; 25 min, 36% A/64% B; 35 
min, 25% A/75% B. 
 
The freeze drying process of the EMCLPs and VCMCLPs was performed on a freeze dryer (Christ 
Alpha 1–2, Martin Christ Gefriertrocknungsanlagen GmbH, Germany) coupled with a vacuum pump 
(rotary vane vacuum pump, Vacuumbrand RZ 2.5, Vacuumbrand GmbH t CO KG, Germany).  
 
The ultrasonication procedure was performed on a probe sonicator (Heat Systems-Ultrasonics Inc., 
Sonicator W-375 Cell Disruptors). All measurements were performed immediately following material 
preparation. 
 
2.3. Synthesis of [VO(C21H19O6)(C10H8N2)(H2O)]2(SO4).2CH3OH.3H2O 
 
The complex [VO(C21H19O6)(C10H8N2)(H2O)]2(SO4).2CH3OH.3H2O (VCur) (Fig. 1) was prepared and fully 
characterized according to previously reported work [36]. 
 
2.4. Synthesis of monodisperse Fe3O4-CA colloidal MNPs 
 
2.71 g (0.010 mol) of FeCl3・6H2O and 1.0 g of FeCl2・4H2O (0.0050 mol) were dissolved separately 
in two closed vessels containing 20 mL of degassed ultrapure H2O pretreated for 30 min with inert 
nitrogen gas bubbling, and then mixed in a three-neck flask under a nitrogen atmosphere. The 
resulting solution was vigorously stirred at 90 °C under reflux for 60 min to avoid development of 
aggregates and large polycrystalline particles. Subsequently, 6 mL of ammonia solution were added 
drop by drop until pH 10.5. The resulting mixture was allowed to stir for 30 min at 90 °C and then 
cooled to room temperature.  
 
A black precipitate was obtained from the reaction mixture via magnetic separation by means of a 
permanent magnet and the supernatant was removed by decantation. The resulting Fe3O4 NPs were 
washed three times with ultrapure H2O, resuspended in 20 mL of degassed ultrapure H2O in a three-
neck flask under a nitrogen atmosphere. To that, 1.1 g (0.0060 mol) of citric acid was added under 
vigorous stirring and the resulting mixture was stirred at 90 °C for 90 min. Then, it was cooled to 
room temperature. Subsequently, 2 mL of ammonia solution was added until pH 7.5 under 
continuous stirring and the mixture was stirred for another 80 min at 90 °C. A dark brown precipitate 
was collected by centrifugation at 9000 rpm for 60 min. The resulting Fe3O4-CA NPs were washed 
three times with ultrapure H2O to remove the excess of CA, and resuspended in 20 mL of degassed 
ultrapure H2O in order to form a ferromagnetic colloidal suspension of concentration 20 mg Fe3O4-
CA NPs.mL-1 H2O. Subsequently, the suspension was stored in a closed dark vessel at 4 °C for further 
use. 
 
2.5. Synthesis of VCMCLPs 
 
VCMCLPs were prepared according to the thin film hydration method [49,50]. More specifically, 21 
mg of DOTAP chloride and 150 μL of EPC (≈3:2 mol/mol) (Fig. 2) were dissolved in 30 mL of a mixture 
of chloroform/methanol 2:1 (v/v) under continuous stirring at room temperature in a closed vessel. 
Subsequently, 10 mg (7.10-6 mol) of VCur diluted in 15 mL of the same mixture of organic solvents 
was added to the above mixture under continuous stirring at room temperature in a 50 mL round-
bottom flask at a≈7:1 total lipid/drug molar ratio (mol/mol). After complete homogenization of the 
mixtures, the organic phase was slowly removed at reduced pressure at 35 °C using rotary 
evaporation, forming a crimson-colored thin lipid film on the inner side of the flask. The flask 
containing the lipid film was left for 2 h under high vacuum for the removal of any organic solvent 
traces. Subsequently, 2 mL of Fe3O4-CA NPs aqueous suspension was dispersed via sonication in 8 mL 
of PBS (pH 7.4), and the resulting suspension was added to the lipid film to hydrate it for 60 min, 
under continuous stirring in a water bath at 37 °C, above the main phase transition temperature (Tt) 
of DOTAP lipids [51], in order to prepare multilamellar vesicles (MLVs). After sufficient hydration, the 
suspensions were vortexed at 1500 rpm for 10 min. Small unilamellar vesicles (SUVs) were prepared 
after sonication of the resultant liposomal suspension (MLVs) for two 5 min periods interrupted by a 
2 min resting period in an ice bath. The resulting SUVs were allowed to stand at room temperature 
for 30 min to anneal any structural defects, and then stored in a closed dark vessel at 4 °C for further 
use. 
 
Empty magnetic cationic liposomes (EMCLPs) were prepared following the same experimental 
procedure without addition of VCur. 
 
2.6. Determination of Fe3O4-CA content 
 
The percentage of iron incorporated into EMCLPs and VCMCLPs was estimated by FAAS. A 0.2 g dry 
sample was placed in a 100 mL polytetrafluoroethylene (PTFE) beaker, 20 mL of 6 N HCl was added 
and boiled for about 1 h until the sample had been completely dissolved. The solution was cooled 
and transferred to a 200 mL volumetric flask. Appropriate dilution was applied if necessary and the 
Fe content was determined according to the standard method 3111 B [52] using the following 
calibration curve: CFe=0.027ABS–0.015 (R2=1), where CFe stands for iron concentration in the sample 
(mg.L-1) and ABS is the absorption of the sample measured at 248.3 nm. Subsequently, the Fe3O4-CA 
content was estimated through combinatorial calculations by using the TGA data for the residual 
quantity of Fe3O4 and the weight loss caused by burning the chemisorbed CA molecules (vide infra). 
 
2.7. Determination of VCur entrapment efficiency and loading capacity 
 
The confirmation of the successful incorporation of VCur inside the liposomal matrices as depicted in 
Fig. 5 (vide infra) and the determination of the encapsulated percentage of VCur into VCMCLPs was 
estimated through HPLC analysis. A 0.02 g dry sample was ground and immersed in a 50 mL PTFE 
beaker, into 30 mL of a mixture of MeOH/DMSO 2:1 (v/v), and then filtered through a 0.2 μm PTFE-
membrane syringe filter. Appropriate dilution was applied for the HPLC measurements and VCur 
content was determined, according to the following calibration curve: CVCur=2・108×peak 
area+136,603 (R2=0.9992), where CVCur stands for VCur concentration in the sample (mg.mL-1) and 
peak area is the area of the sample measured at 480 nm. 
 
The entrapment efficiency of VCur was calculated using the following equation: Entrapment 
Efficiency (%)=VCuri/VCurt x 100, where VCuri is the amount of VCur incorporated into VCMCLPs and 
VCurt is the initially added amount of VCur. 
 
The loading capacity of VCur was calculated using the following equation: Loading Capacity 
(%)=VCuri/WVCMCLPs x 100, where VCuri is the amount of VCur incorporated into VCMCLPs and 
WVCMCLPs is the weight of the synthesized VCMCLPs after freeze drying.  
 
Experiments were carried out in triplicates and the results were expressed as mean  standard 
deviation (SD). 
 
2.8. In vitro VCur release study 
 
The drug release profile of VCur from VCMCLPs was performed as follows: 0.02 g of VCMCLP powder 
was ground and immersed into 30 mL of oxygenated (O2, 100%) PBS solution, pH 7.4. The 
temperature of the release medium was set at 37  1 °C, under continuous stirring at a rate of ca. 
300 rpm. Aliquots of 2 mL of supernatant were taken at predetermined time intervals. Following 
removal of insoluble solid VCMCLPs by centrifugation (13,000 rpm, 1 min) and filtration (0.2 μm 
PTFE-membrane syringe filter), the remaining clear solution was analysed and the amount of VCur 
released was determined by HPLC, with the aid of the previous calibration curve (vide supra). 
Experiments were carried out in triplicates and the results were expressed as mean  SD. 
 
2.9. Circular dichroism 
 
Circular dichroism (CD) spectra of CT-DNA were recorded in the range 180-500 nm at 25 °C on a 
JASCO J-715 spectropolarimeter equipped with Peltier temperature regulation system. CD spectra 
were acquired with four accumulations, using quartz cuvettes with 1.0 cm optical path length, scan 
speed of 100 nm.min-1 and 1 s response time. Data were analyzed with the standard Jasco software 
package. Experiments were performed in PBS (final concentration of 2% DMSO) by keeping the DNA 
concentration constant (5×10-5 M) while varying the concentration of compounds (0-2.5×10-5 M) to 
achieve ratios R=[compound]/[DNA] of 0.0, 0.01, 0.05, 0.1, 0.2, 0.33, 0.5. 
 
2.10. DNA melting 
 
DNA melting temperature measurements were performed using a Varian Cary 300 
spectrophotometer equipped with a heating multiple cell block apparatus. Temperatures were 
maintained under computer control and were increased at a 0.5 °C.min-1 rate. DNA melting 
experiments were carried out by monitoring the absorbance of DNA at 258 nm in the temperature 
range from 25.0 °C to 95.0 °C. Solutions were allowed to equilibrate for 1 min at each temperature. 
Cuvettes (1.0 cm capped quartz) were mounted on a thermal block and the solution temperatures 
were monitored by a thermistor in the reference cuvette. The melting temperature (Tm) of DNA was 
determined as the midpoint of the optically detected transition and the measurement was repeated 
three times for each sample. The thermal melting experiments were performed in phosphate buffer 
solution (final concentration of 2% DMSO) by keeping the DNA concentration constant (5×10-5 M) 
while varying the concentration of compounds (0-2.5×10-5 M) to achieve ratios 
R=[compound]/[DNA] of 0, 0.01, 0.05, 0.1, 0.33, 0.5. 
 
2.11. Ethidium bromide 
 
For competitive binding between ethidium bromide (EB, Sigma Aldrich, USA), DNA was pretreated 
with EB in the ratio of [DNA]/[EB]=1.3:1 ([DNA]=5×10-5M and [EB] =3.85×10-5 M) for 10 h at room 
temperature. The compounds (0–1.5×10−4 M) were then added to DNA-EB mixture to achieve ratios 
R=[compound]/[DNA] of 0, 0.01, 0.05, 0.1, 0.2, 0.33, 0.5, 1, 3 and their effect on the emission 
intensity was measured using a Hitachi F-2500 spectrofluorimeter at 25 °C, in the wavelength range 
550–700 nm. The excitation wavelength of the samples was 520 nm, the scan speed was 300 
nm.min-1, and both excitation and emission slit widths were 2.5 nm. In addition, fluorescence 
spectra of the compounds alone, of EB alone, and of mixtures of EB with the compounds at the 
concentrations employed in the competitive binding studies were obtained to help in the 
interpretation of our results. 
 
2.12. Viscosity measurements 
 
Viscosity measurements were carried out using Ostwald's viscometer (micro-Ubbelohde, SI 
ANALYTICS) at 25 °C. The viscometer was thermostated at 25.0 •} 0.1 °C in a constant temperature 
bath. Flow time of solutions was measured with a digital stopwatch, each sample was measured 
three times and an average flow time was calculated. The values did not differ by>0.2 s from each 
other. All solutions were filtered through 1 μm filters (Millipore Acrodisc) prior to the 
measurements. Experiments were carried out in phosphate buffer solution (final concentration of 
2% DMSO) by keeping the DNA concentration constant (5×10-5 M) while varying the concentration of 
compounds (0-2.5×10-5 M) to achieve ratios R=[compound]/[DNA] of 0, 0.01, 0.05, 0.1, 0.2, 0.33, 0.5. 
The intrinsic viscosity [n] was calculated according to the relationship [n]=(t - tb)/tb, where tb is the 
flow time for the buffer and t is the observed flow time for DNA in the presence or absence of the 
compounds. Data were presented as (n/no)1/3 versus R, where n and n0 are the intrinsic viscosities 
in the presence or absence of the compounds. For the low DNA concentrations used in these 
experiments, the intrinsic viscosity [n] is proportional to the difference in the flow times for the 
buffer with and without DNA, resulting in the following Eq. (2) [53]. 
 
 
 
where L and Lo are the DNA lengths and [n] and [no] are the intrinsic viscosities with and without 
the compound. The tb, to and t are the flow times of the buffer, the plain DNA and the 
DNA/compound solution, respectively. 
 
3. Results 
 
3.1. Synthesis 
 
Fe3O4 NPs (core) (Scheme 1) were prepared via the co-precipitation method of ferric chloride and 
ferrous chloride (2:1 molar ratio) in the presence of excess ammonia solution according to a 
modified Massart method [54,55]. The surface of the obtained magnetite NPs was stabilized by a 
direct CA addition in order to obtain a ferromagnetic colloidal suspension of Fe3O4 NPs, surface-
modified with carboxylic moieties (Scheme 1). Surface functionalization with carboxylates offers the 
potential of achieving the required repulsive forces that can prevent agglomeration of the emerging 
superparamagnetic NPs and lead to the formation of a thermodynamically stable colloidal 
suspension (Scheme 1). 
 
The pH of the reaction during Fe3O4 NP synthesis was high enough (pH=10.5) in order to prevent 
agglomeration due to surface charge, since the isoelectric point of Fe3O4 depends on pH (6 ≤ pH ≤ 7), 
Fe2+ concentration and temperature [56,57]. Both, co-precipitation and surface modification 
procedures were carried out in the liquid phase, to avoid NP surface passivation, under a nitrogen 
atmosphere reflux at 90 °C to ensure anaerobic conditions, and under vigorous magnetic stirring for 
better reagent homogeneity.  
 
Scheme 1. a) Chemical equation leading to the synthesis of Fe3O4 NPs, and b) schematic illustration 
of their further functionalization to a colloidal suspension of Fe3O4-CA NPs. 
 
During surface modification with CA, the pH of the reaction was adjusted to near physiological (pH 
7.5) as the NP stability in aqueous media is enhanced near physiological pH [58]. 
 
 
Fig. 3. Schematic illustration of a VCMCLP. The aqueous internal cavity is presented in blue color, 
and the lipid bilayer is presented in red color. (For interpretation of the references to color in this 
figure legend, the reader is referred to the web version of this article.) 
 
The obtained Fe3O4-CA NPs were physicochemically characterized through a series of 
complementary techniques in order to: a) verify the successful CA surface modification of the 
magnetite NPs (FT-IR, powder XRD, XPS), b) confirm the preservation of the superparamagnetic 
character of the emerged ferromagnetic colloidal suspension (magnetization measurements), c) 
specify the size, shape, and surface charge of the CA stabilized Fe3O4 NPs (TEM, SEM, DLS, z-
potential), and d) determine the thermal stability and the amount of CA absorbed on the surface of 
Fe3O4 NPs (TGA). 
 
VCMCLPs (Fig. 3) were prepared after initial incorporation of VCur into the emerging lipid mixture of 
low concentration in DOTAP and EPC and the subsequent formation of magnetic MLVs via the thin 
film hydration method, with the addition of a PBS colloidal suspension of Fe3O4-CA NPs. Subsequent 
sonication of the resulting MLVs led to the formation of SUVs. As presented in Fig. 3, VCur due to its 
hydrophobic nature is encapsulated in the bilayer membrane. The ferromagnetic colloidal 
suspension of Fe3O4-CA NPs is encapsulated in the aqueous interior of the LP. It has been reported 
that the utilization of both DOTAP and EPC lipids at low concentrations produces formations with 
broad size distributions [40]. Additionally, the combination of the corresponding lipids results in 
significantly high LP uptake efficiencies against cancer cells by regulating the physicochemical profile 
of lipid bilayers, stabilizing the liposomal structure, and optimizing LP fusion with the plasma 
membrane [40,41]. The effective liposomal encapsulation aims at enhancing VCur aqueous solubility 
and therefore its systemic bioavailability, circulation time, targeted delivery, and therapeutic 
potential (Fig. 4). 
 
Fig. 4. VCur dispersed in H2O (left), VCMCLPs dispersed in H2O (right). Liposomal encapsulation of 
VCur enhances its solubility and thus its bioavailability. 
 
 
The obtained VCMCLPs were characterized via magnetization measurements in order to define the 
role of LP encapsulation in the preservation of the superparamagnetic character of the encapsulated 
Fe3O4-CA NPs. TEM, SEM, DLS, and z-potential measurements were employed to further determine 
the morphological characteristics and the changes in the charge of the prepared liposomal 
formulations after the incorporation of VCur and the magnetic load in the liposomal bilayer and 
aqueous interior, respectively. TGA and FAAS measurements indicated the thermal stability and the 
amount of the encapsulated Fe3O4-CA NPs in the hydrophilic interior of the CLPs. Entrapment 
efficiency, loading capacity and release rate of VCur were determined by HPLC studies that further 
confirm the structural integrity of the VCur molecule during the encapsulation and release 
processes. 
 
  
3.2. FT-IR spectroscopy 
 
The FT-IR spectra of CA and Fe3O4-CA NPs are presented in Fig. 6, and confirm the effective surface 
modification of magnetite NPs with CA. More specifically, in the spectrum of CA the rather broad 
vibration bands are indicative of the strong inter- and intramolecular hydrogen bonding. The broad 
absorption bands at 1728 cm-1 and 1412 cm-1 are assigned to the C]O antisymmetric and symmetric 
stretching vibrations of the COOH moiety, respectively. In the spectrum of Fe3O4-CA NPs the weak 
absorption band at 2919 cm-1 is attributed to the CH2 stretching. The absorption band for the 
antisymmetric vibrations of the carboxylate carbonyls emerges at 1613 cm−1. Symmetric vibrations 
for the same group appear at 1399 cm-1. The observed carbonyl vibrations are shifted to lower 
frequency values in comparison to the corresponding vibrations in free CA, suggesting changes in the 
vibrational status of the citrate ligand binding to the magnetite surface by a pHsensitive 
chemisorption [59–62], through complexation of CA with iron, thus ascribing a partial single bond 
character to the C]O bond [63,64]. The broad band at 562 cm-1 can be attributed to the Fe-O 
stretching vibrations of Fe3O4 [65]. 
 
3.3. X-ray diffraction 
 
The X-ray diffraction patterns of Fe3O4-CA NP, EMCLP and VCMCLP dried powder samples are 
presented in Fig. 7. The Fe3O4-CA NP sample (Fig. 7A) exhibits broad diffraction peaks, due to the 
small crystallite size, indexed as Fe3O4 (magnetite) according to JCPDS-ICDD Powder Diffraction File 
19-0629. In EMCLP and VCMCLP samples (Fig. 7B and C) where the CA-modified magnetite NPs are 
encapsulated into the LPs, the peaks become very broad and only the diffraction peaks of the 
strongest reflections are visible above the background. 
 
3.4. Magnetization measurements 
 
From magnetization loops, the superparamagnetic character of Fe3O4-CA NP, EMCLP and VCMCLP 
dried powder samples at room temperature was verified. This is expected for the particle size of the 
oxide core, since the critical size, Dsp, for superparamagnetism, with measuring time ~100 s, is 20-30 
m for iron oxide particles [66]. Superparamagnetism, the thermally activated reversal of particle 
magnetization, is manifested as diminishing coercivity, while magnetization remains high, and the 
isothermal magnetization curve obeys a Langevin function. 
 
The blocking temperature, TB, determined by Zero-Field-Cooled thermomagnetic measurements 
with a 100 Oe (8 kA/m) field, is ≈ 255 K. Room temperature coercivity, shown in the insets of Fig. 8A–
F, is negligible, as low as 4–5 Oe (320-400 A.m-1). At 50 K the thermal reversal of magnetization is 
blocked and a magnetic hysteresis loop is obtained for all three samples, with a coercivity of 145–
160 Oe (11.6–12.8 kA.m−1). The specific magnetization of the iron oxide core in Fe3O4-CA NPs at the 
maximum field (3 T) at room temperature is 65.9 emu.g-1, a value corresponding to 80% of the 
magnetization of bulk magnetite. A wide range of magnetization values, lower than the bulk ones, 
are reported for iron oxide NPs [67]. Magnetite (Fe3O4), with an inverse spinel ferrite structure, has 
a magnetic moment of 4 μB per f.u., which gives a theoretical value of specific saturation 
magnetization Ms 96 emu.g-1 (Am2.kg-1) at 0 K. Magnetite oxidizes to maghemite (γ-FeO3), an iron 
deficient spinel with lower magnetization [68]. At the surface of magnetite particles, a thin 
maghemite shell may form, thus reducing NP magnetization [69]. Due to the high surface area to 
volume ratio of NPs, magnetization is strongly dependent on size and diminishes with decreasing 
size, since the magnetic moments of surface atoms are not aligned to those of the core. Besides 
surface spin disorder [70], the additional mass of the non-magnetic CA capping layer reduces 
magnetization, while LP encapsulation also affects magnetization [71]. 
 
 
Fig. 5. HPLC spectrum of free VCur (light blue line) and released VCur (black line). (For interpretation 
of the references to color in this figure legend, the reader is referred to the web version of this 
article.) 
 
 
Fig. 6. FT-IR spectra of CA and Fe3O4-CA NPs. 
 
  
 
Fig. 7. A) XRD pattern of Fe3O4-CA NPs, B) XRD pattern of EMCLPs, C) XRD 
pattern of VCMCLPs. 
 
 
Fig. 8. Magnetization measurements of: A) Fe3O4-CA NPs at 50 K and B) 300 K, C) EMCLPs at 50 K 
and D) 300 K, E) VCMCLPs at 50 K and F) 300 K. The magnetic field range in the inset graph is −1000 
to +1000 Oe. 
 
3.5. XPS analysis 
 
The XPS spectrum of prepared films of Fe3O4-CA NPs on Si is shown in Fig. 9A. The spectrum shows 
strong C 1s and O 1s peaks, along with Fe 2p, Si 2p, and weak signals from N 1s, K 2s, Cl 2p and P 2p. 
The K, Na, Cl and P peaks originate from the phosphate saline buffer, and the Si is from exposed 
areas of the underlying substrate. Higher resolution scans over the Fe 2p, C 1s and O 1s peaks are 
shown in Fig. 9B, C, and D, respectively. The Fe 2p spectrum shows the expected 2p3/2-2p1/2 doublet, 
with a separation of approximately 13 eV and a 2p3/2 binding energy of approximately 711.0 eV 
typical of Fe3O4. The asymmetry of the peaks and presence of shake-up intensity on the high binding 
energy side of the peak confirm this identification. The C 1s peak shows a main component at 285.0 
eV due to carbon in C-C bonds, with weaker components at approximately 286.8 eV due to carbon in 
C-O bonds and 288.9 eV due to carbon in COO− acid groups. These chemical groups are consistent 
with the presence of CA. This is in agreement with the form of the O 1s peak shown in Fig. 9D. The 
main component at 532.2 eV is attributed to oxygen bound to carbon in an organic group consistent 
with the presence of C-O or COO− bonds, not separately resolvable. The lower binding energy 
component at 530.1 eV is indicative of Fe3O4, and the weaker component at approximately 534.4 eV 
is a weak X-ray excited KVV Auger peak from the low level of Na present on the sample. 
 
 
Fig. 9. XPS spectra of Fe3O4-CA NPs: A) survey, B) Fe 2p, C) O 1s, D) C 1s. 
 
3.6. TEM analysis 
 
The diameters of Fe3O4-CA NPs and VCMCLPs were determined by TEM as presented in Fig. 10A–D. 
TEM observations confirmed that Fe3O4-CA NPs exhibit uniform spherical morphology and relatively 
narrow size distribution with an average particle size around 16  5 nm. The fractal structure of the 
depicted Fe3O4-CA NP aggregates implies gelation and chain-formation process of individual NPs to 
submicron clusters, thus denoting the agglomeration tendency of the emerged MNPs [72–74]. The 
consecutive centrifugations throughout the synthetic procedure, the application of an external 
magnetic field due to the magnetic agitation during the ferromagnetic phase of stabilization with CA, 
and the subsequent drying process that precedes TEM measurements may account for the increased 
tendency towards agglomeration [61]. TEM images of the VCMCLP sample indicate the presence of 
predominantly distinct liposomal nano-formulations with spherical morphology and an average size 
between 70-120 nm, and the existence of scattered agglomerates with no specific shape and size. 
The observed mean diameter of the spherical NPs is typical of the utilization of cationic lipids in the 
synthetic procedure [75], and representative of the SUV mean diameter range [76]. 
 
 
Fig. 10. TEM images of: A) Fe3O4-CA NPs at 50 nm and B) 20 nm, C) VCMCLPs at 1 μm and D) 0.5 μm. 
 
3.7. DLS and z-potential 
 
For comparative purposes, DLS was employed to further determine the particle size of Fe3O4-CA NP, 
EMCLP and VCMCLP samples as presented in Fig. 11A–C. It is well documented that utilization of 
MNPs can significantly affect the size and charge of the emerging liposomal nanocarriers [77,78]. As 
a result, the amount of the incorporated magnetic load into the liposomal interior should be 
efficiently controlled in order to develop liposomal formulations a) with maintained size and charge, 
and b) sufficiently responsive to an applied external magnetic field. Furthermore, changes in LP 
dispersity index and size provide useful information on the modifications of the liposomal bilayer. 
The results at hand show that the mean hydrodynamic size of Fe3O4-CA NPs is 87 1.4 nm with a 
stable polydispersity index (PI) σPI=0.224  0.014, thus indicating the presence of large clusters as a 
result of agglomeration promoted by the high concentration of magnetic NPs in the buffer solution. 
The characteristic stability of Fe3O4-CA NP polydispersion is mainly due to the robust coating formed 
on the magnetite surface by the coordinated to iron carboxylate groups of CA and the presence of 
uncoordinated carboxylates of CA in direct contact with the aqueous medium [73,79,80]. The mean 
hydrodynamic size of EMCLPs is 109  10.3 nm, with PI σPI=0.272 0.024, indicating the presence of 
scattered agglomerates in the buffer solution. In the case of VCMCLPs, the mean hydrodynamic size 
is 181 18.1 nm, with PI σPI=0.286  0.036, also implying the presence of scattered aggregates in the 
buffer solution. The observed difference between the size of VCMCLPs and that of EMCLPs can be 
attributed to the VCur load. 
 
Zeta-potential measurements were conducted immediately after determination of particle size. It 
has been observed that CA-surface modification of magnetite NPs results in highly negative surface 
charged Fe3O4-CA NPs (−29.75  5.45 mV at pH 7.4), due to the presence of negatively charged CA 
carboxylates on the surface of magnetite NPs [60,81]. Zeta-potential for EMCLPs was measured to 
be 32.7  6.32 mV. The observed decrease of zeta-potential for the EMCLP sample compared to 
literature reported zeta-potential values of CLPs [41] indicates partial neutralization by addition of 
the negatively charged Fe3O4-CA NPs. In the case of VCMCLPs, the zeta-potential was measured to 
be 38.3  8.23 mV. This increase of zeta-potential compared to the EMCLP sample can be attributed 
to alterations of the structural integrity of the LP bilayer induced by the encapsulation of VCur 
[82,83], and the positive charge of the encapsulated VCur species [VO(C21H19O6)(C10H8N2)]+ [36]. 
 
Fig. 11. Particle size distribution of: A) Fe3O4-CA NPs, B) EMCLPs, and C) VCMCLPs. 
 
3.8. SEM analysis 
 
The morphologies of all samples were examined by SEM. Fig. 12 presents SEM images of the 
morphology of Fe3O4-CA NPs (Fig. 12A–B), EMCLPs (Fig. 12C–D), and VCMCLPs (Fig. 12E–F), 
respectively. The Fe3O4-CA NP sample projects large, dense aggregates of agglomerated uniform 
spherical NPs, with a relatively narrow size distribution. SEM images of the EMCLP and VCMCLP 
samples indicate a fluffy arrangement of the densely agglomerated spherical powder particles that 
form micron-sized aggregates of no specific shape and structure. This is mainly due to the 
lyophilization process that promotes fusion of the phospholipid membranes of the CLPs and the 
ensuing creation of an amorphous lipid cake, eliminating the distinctiveness of the liposomal vesicles 
[84,85].  
 
3.9. Thermal studies 
 
The thermal decomposition of Fe3O4-CA NPs, EMCLPs, and VCMCLPs was studied by TGA under an 
atmosphere of air (Fig. 13). The Fe3O4-CA NPs sample was stable up to 30 °C. The observed weight 
loss of about 7.1% between 30 °C and 130 °C could be attributed to the removal of the physisorbed 
CA and water molecules. Further weight loss of about 12.9%, between 130 °C and 524 °C, pointed to 
the decomposition of the chemisorbed CA molecules. A negligible weight loss of about 1.5% beyond 
520 °C was due to the Fe3O4-Fe2O3 phase transformation [60]. The EMCLP sample was stable up to 
30 °C. The observed weight loss of about 26.4%, between 30 °C and 185 °C, was due to the loss of 
the physisorbed water and CA molecules. At higher temperatures, between 185 °C and 526 °C, 
burning of the organic structure of the LPs and the chemisorbed CA molecules also contributed to a 
further weight loss of about 22.5%. Further weight loss of about 7%, beyond 526 °C, could be 
attributed to the aforementioned Fe3O4-Fe2O3 phase transformation. 
 
The VCMCLP sample was stable up to 30 °C. The observed weight loss of about 10.8%, between 30 
°C and 170 °C, was due to the loss of the physisorbed water and CA molecules. At higher 
temperatures, between 170 °C and 493 °C, further weight loss of 37.1% was attributed to the 
burning of the organic structure of the LPs, the encapsulated VCur molecule, and the chemisorbed 
CA molecules. Further weight loss of about 6.3%, beyond 493 °C, could be attributed to the Fe3O4-
Fe2O3 phase transformation. The violent reaction observed beyond 680 °C could be related to 
changes of the crystalline structure of the encapsulated VCur molecule as also observed in our 
previous experimental work [36]. The described tentative assignments were consistent with 
previously reported results of thermogravimetric analysis [86]. 
 
3.10. Fe3O4-CA content 
 
The in situ Fe3O4-CA NP loading efficiency for the EMCLP and VCMCLP samples was determined 
through FAAS and TGA and estimated to be 121 mg Fe3O4-CA NPs per 1 g of EMCLPs and 141 mg 
Fe3O4-CA NPs per 1 g of VCMCLPs. 
 
3.11. VCur entrapment efficiency and loading capacity 
 
The in situ entrapment efficiency and loading capacity of VCur in VCMCLPs was estimated to be 38% 
and 9.5%, respectively. The observed relatively low encapsulation efficiency and loading capacity are 
probably due to: a) the bulk structure of VCur complex that limits sufficient entrapment inside the 
bilayer membrane of the emerged LPs, b) the repulsive forces caused by the positive charge of the 
VCur complex and the cationic liposomal vesicles, c) the utilization of EPC in the synthetic procedure 
of the specific LPs that leads to the formation of liposomal formulations with reduced entrapment 
efficiency, as also observed in other literature reports [82], and d) the selected low lipid- to-complex 
ratio that was employed during the preparation of the VCMCLPs that consequently leads to lower 
entrapped drug [87]. 
 
 
Fig. 12. SEM images of: A) Fe3O4-CA NPs at 400 nm and B) 200 nm, C) EMCLPs at 10 μm and D) 3 μm, 
E) VCMCLPs at 10 μm and F) 2 μm. 
 
  
3.12. In vitro VCur release study 
 
The release profile of the active ingredient (VCur) is an important factor for the modulation of the 
VCMCLP pharmacokinetic behavior. The evaluation criteria of the release profile should include: the 
total amount of VCur released and release rate. Fig. 14 shows the percentage of VCur released with 
regard to the total entrapped VCur versus time. The equilibrium release percentage of VCur from 
VCMCLPs was estimated to be around 10.53%. A closer examination of the release profile during 48 
h of study shows that the drug release rate was high up to about 12 h, then the process got slower 
and the rate significantly decreased. The low release percentage of VCur can be attributed to its 
hydrophobic nature and its facile accommodation into the hydrophobic environment of the 
liposomal bilayer, a region where contact with aqueous media is limited [41]. Furthermore, the 
positive charge on the surface of the liposomes may exert an electrostatic repulsive effect on VCur, 
hindering its passage through the lipid layer and release in the outer medium. 
 
 
Fig. 13. TGA diagrams of: Fe3O4-CA NPs (black line), EMCLPs (red line), VCMCLPs (blue line). (For 
interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.) 
 
3.13. Circular dichroism studies 
 
Circular dichroism (CD) is a spectroscopic technique widely used to study the structure and 
interactions of biomolecules, like DNA [88]. The spectrum of CT-DNA in its typical B-form consists of 
a positive band one at 275 nm, due to base-stacking and a negative one at 245 nm due to right-
handed helicity [89]. The effect of the VCur complex on the native structure of DNA was studied first 
to serve as reference for the evaluation of the interaction of the VCur-loaded magnetic cationic 
liposomes (VCMLPs). CD spectra of CT-DNA were recorded at increasing [VCur]/[DNA] ratios (R=0, 
0.01, 0.05, 0.1, 0.2, 0.33, 0.5) and are shown in Fig. 15A. It is obvious that no major changes are 
observed in the CD spectra of DNA with the exception of a bathochromic shift of the positive band 
by 2 nm and of the negative band by 1 nm. As can be seen in Fig. 15B, upon addition of VCMLPs 
changes are observed in both positive and negative bands of CT-DNA. In particular, the intensity of 
positive band is increased in a dose-dependent way, reaching at the highest ratio of R=0.5 an 
increase of 40% relative to its initial height. The intensity of the negative band initially decreases in 
intensity and subsequently increases, at the higher VCMLP concentrations. A gradual bathochromic 
shift of the negative band approx. 3 nm and of the positive band by 2 nm is also recorded upon 
increasing VCMLP concentration. No induced CD was generated and at all ratios, furthermore, both 
negative and positive bands are present indicating that CT-DNA retains the basic B-form 
characteristics. It should also be noted that no changes were observed in the CD spectra of DNA 
upon addition of Fe3O4-CA NPs and EMCLPs, that served as control. 
 
 
 
Fig. 14. Cumulative release percentage of VCur with regard to the total entrapped VCur vs. time. 
 
 
Fig. 15. Circular dichroism spectra of DNA (5×10-5 M) with increasing amounts of A) VCur and B) 
VCMCLPs. The ratios R=[compound]/[DNA] employed ranged from 0 to 0.5. For clarity, the spectra 
from only four Rs are presented in the figure. 
 
 
Fig. 16. Thermal denaturation data (ΔTm) of CT-DNA (5×10-5 M) upon addition of VCur, VCMCLPs, 
EMCLPs and Fe3O4-CA NPs with ratios R [compound]/[DNA] ranging from 0 to 0.5. 
 
3.14. Thermal denaturation studies 
 
Interactions of small molecules with DNA may alter its melting temperature (Tm) reflecting to some 
extent the strength and mode of binding [90]. Thermal denaturation experiments were carried out 
to investigate the effect of VCur and VCMLPs on the stability of the CTDNA duplexes. For CT-DNA 
alone, under our experimental conditions, a Tm of 70.35  0.25 °C was recorded a value in good 
agreement with the literature [91]. The addition of increasing concentrations of VCur and VCMLPs 
(R=0, 0.01, 0.05, 0.1, 0.33, 0.5) resulted in increased Tm values relative to CT-DNA, reaching at the 
highest ratio of R=0.5 ΔTm values of 2.99 and 5.99 °C, respectively (Fig. 16). In the presence of 
increasing concentrations of Fe3O4-CA NPs and EMCLPs, no significant changes were recorded for 
the Tm values. 
 
3.15. Fluorescence spectroscopic studies 
 
Competitive binding experiments, based on the quenching of fluorescence of the known intercalator 
ethidium bromide (EB) upon displacement from the DNA base pairs and interaction with the solvent 
molecules, were also run [92]. Fig. 17 shows the effect of increasing concentration of VCur and 
VCMLPs on the fluorescence intensity of EB bound to CT-DNA. It is obvious from the graph that the 
fluorescence intensity of DNA-EB reduces upon addition of VCur and VCMLPs and this effect 
increases with increasing concentration of the above compounds reaching 20 and 28% for R=3, 
respectively. The substantial decrease in fluorescence intensity of EB indicates that both VCur and 
VCMLPs displace EB from the base pairs and shows the presence of intercalative binding. It should 
be noted that the addition of increasing concentrations of Fe3O4-CA NPs and EMCLPs induce 
absolutely no displacement of EB bound to CT-DNA. Furthermore, all the studied compounds do not 
have any effect on the emission of EB in the absence of DNA at all concentrations tested (data non-
shown). 
3.16. Viscosity measurements 
 
To further investigate the mode of binding of VCur and VCMLPs with CT-DNA, viscosity 
measurements were carried out. Intercalation of a compound between the DNA base pairs causes 
unwinding and lengthening of the DNA helix, resulting in changes of the hydrodynamic properties of 
DNA that can be monitored using viscosity studies [93]. Viscosity measurements were carried out on 
CT-DNA by varying the concentration of the added compounds to achieve ratios 
R=[compound]/[DNA] of 0, 0.01, 0.05, 0.1, 0.2, 0.33, 0.5. The values of relative specific viscosity 
(n/no)1/3 (where n is the viscosity of DNA in the presence of each compound examined and no is 
the viscosity of DNA alone) were plotted against R according to the theory of Cohen and Eisenberg 
[53] and are presented in Fig. 18. As can be seen, with increasing amounts of VCur and VCMLPs, the 
relative viscosity of DNA increases continuously, more profoundly in the case of VCMLPs. The 
significant increase in DNA viscosity which is comparable to that of known intercalators [92], 
provides strong evidence for binding to DNA through the intercalation mode. It is obvious from the 
data in Fig. 18 that the presence of increasing concentrations of Fe3O4-CA NPs and EMCLPs do not 
alter the effective length of DNA molecule. 
 
4. Discussion 
 
LPs constitute a specific category of nanocarriers with exceptional properties in terms of size, 
biocompatibility, drug loading capacity and surface functionalization, widely used for the 
encapsulation of therapeutic agents and drugs for cancer treatment. Several research groups have 
reported the successful encapsulation of anticancer drugs including bleomycin, cisplatin analogues, 
daunorubicin, doxorubicin in targeted drug delivery liposomal systems [94–98]. CLPs, even though 
mainly applied as gene delivery systems for transfection due to their ability to be adsorbed onto the 
surface of the cells and fuse with the negatively charged cellular membranes [99–104], have also 
been employed for the intracellular delivery of known pharmacophores [105–107] and, more 
recently, for the delivery of bioactive metal complexes [41–43,108]. The embedment of MNPs into 
the liposomal structure can lead to the development of nano-formulations with magnetic targeting 
activity for efficient drug release to specific biological sites [109–116]. Within this framework, a 
homogeneous and welldispersed aqueous suspension of superparamagnetic magnetite NPs surface 
functionalized with CA, was utilized for the first time, as the magnetic core for the generation of 
targeted anticancer magnetic cationic liposomal nanocarriers. The VCur complex utilized as the 
encapsulated molecule, is the third crystallographically reported oxovanadium(IV)-curcumin 
complex which combines the anticancer potential of curcumin and vanadium in one entity and 
which has demonstrated anti-ROS, anti-oxidant and DNA degradation activity [36]. However, this is 
the first time that a metal complex based on curcumin is encapsulated in MCLPs. Both the complete 
physicochemical characterization of VCur and its demonstrated in vitro activity provide a solid basis 
for the generation of novel well-characterized nano-formulations with anticancer potential. 
 
Indeed, the hybrid nanocarrier had exceptional stability in physiological media and presented 
enhanced solubility of the anticancer metallodrug compared to free VCur as evidenced through the 
entrapment efficiency and loading capacity results and the in vitro release studies. Furthermore, the 
generated MCLPs preserved the superparamagnetic behavior of the employed MNP core, an 
advantageous feature for magnetic targeting applications. Even though individual properties may be 
further optimized, the generated VCMCLPs already meet the physicochemical and morphological 
requirements for targeted drug delivery applications [117]. 
 
 
Fig. 17. Emission spectra of the DNA–EB complex ([DNA]:[EB]=1.3:1 ([DNA]=5×10-5 and 
[EB]=3.85×10-5 M) in the presence of increasing concentrations of A) VCur and B) VCMCLPs. The 
employed ratios R=[compound]/[DNA-EB] are shown on the figure. 
 
 
Fig. 18. Effect of increasing amounts of VCur, VCMCLPs, EMCLPs, and Fe3O4-CA NPs on the relative 
viscosity of CT-DNA (5×10-5 M) at 25 °C with ratios R=[compound]/[DNA] ranging from 0 to 0.5. 
 
Moreover, the biological evaluation of the generated CLPs revealed interesting properties through 
the studies of their interaction with CTDNA. It is known that CLPs are being investigated as nonviral 
vectors for the delivery of therapeutic genes, as they bind and condense DNA spontaneously to form 
CLP–DNA complexes capable of transfecting cells [118,119]. At the ratios R=[VCMCLPs]/[DNA] of 
0.01–0.5 (based on released VCur) employed in our case, no sign of DNA condensation was evident 
in the CD spectra where the spectral profile of Bform DNA was preserved even at the highest R=0.5 
showing that the quantity of LPs present has no major effect on DNA structure. The same was 
observed in the studies with EMCLPs. 
 
The capacity of the VCur cargo to interact with DNA was studied first to serve as base for the 
assessment of the DNA-binding properties of the MCLPs with the independent biophysical methods 
of CD, DNA melting, fluorescence competitive studies with EB, and DNA viscosity measurements. The 
increase in Tm (2.99 °C at R=0.5) indicative of stiffening of the helix, the decrease in EB fluorescence 
(~20% at R=3) indicative of the displacement of EB from the DNA base pairs, as well as the increase 
of relative DNA viscosity (1.25 at R=0.5) indicative of DNA elongation, strongly suggest binding of 
VCur through intercalation. The CD data, despite the lack of major changes, are also in agreement 
with the intercalative mode of binding through the bathochromic shifts of both positive and negative 
bands and the lack of an ICD. As curcumin and curcuminoids are groove binders [120–122] and metal 
complexes containing curcumin as the main organic ligand are also shown to be groove binders 
[123], intercalation appears to mainly involve the aromatic nitrogen co-ligand 2,2′-bipyridine. Metal 
complexes with 2,2′-bipyridine and its derivatives in their coordination sphere are known to interact 
with DNA through intercalation [124–126]. In the case of the VCur complex, concurrent interaction 
of the complex with the grooves through the coordinated curcumin cannot be excluded, even 
though groove binding of curcumin and curcumin complexes is usually accompanied by an induced 
CD signal which was not observed in our case [97]. The effect of VCur on DNA, especially in relation 
to the viscosity data, appears to be more pronounced than that displayed by other oxovanadium(IV) 
complexes in the literature suggested to interact through the intercalative mode [34,127,128], as 
well as other curcumin/curcuminoid complexes with intercalation potential [125,129,130]. Even 
though literature comparisons are not always exact due to differences in experimental details and 
handling, the relatively strong DNA interaction displayed by VCur is worth highlighting. The data on 
the action of VCur on DNA are in agreement with our previous findings on the involvement of VCur 
in genotoxic effects, namely, lethal DNA damage in Escherichia coli [36]. 
 
The DNA interaction data from all biophysical assays were much more pronounced when the 
VCMCLPs were used. As the VCMLPs alone at the concentrations employed do not cause any effect 
on DNA in all assays, the enhanced interaction necessarily involves the VCur complex, the action of 
which is enhanced when administered as the liposomal cargo. The higher VCur effect observed with 
the VCMCLPs may be attributed to electrostatic interactions between the positively charged LPs and 
the negatively charged phosphate backbone of DNA, which result in accumulation of the LPs in the 
vicinity of DNA and consequent increase of the local effective concentration of VCur released at the 
DNA site. Electrostatic interactions have been employed to bind positively charged NPs on DNA for a 
variety of biological applications, like inhibition of DNA polymerase action or functional DNA 
recognition by proteins [131]. To our knowledge this is the only work suggesting that positively 
charged liposomal NPs generate increased concentration of their cargo at the DNA site, offering a 
further dimension in the importance of CLPs as nanocarriers. 
 
5. Conclusions 
 
In the pursuit of the development of advanced type of long-life, stable, bioavailable nanocarriers of 
vanadium metallodrugs, containing metal-bound natural substrates such as curcumin, novel VCur-
loaded cationic targeted-magnetoliposomes were synthesized, physicochemically characterized and 
biologically evaluated as DNA binding agents. The biocompatible and bioavailable nature of the 
emerged liposomal nano-formulations, their magnetic targeting potential, and their capacity to 
favorably interact with DNA indicate the ability of LPs to function as efficient nanocarriers of 
bioactive metal complexes, and render them ideal nano-platforms for further investigations towards 
therapeutic applications against cancer. 
 
Abbreviation list 
 
MNPs  Magnetic nanoparticles 
NPs  Nanoparticles 
SPIO  Superparamagnetic iron oxide 
LPs  Liposomes 
MLPs  Magnetoliposomes 
CLPs  Cationic LPs 
PDT  Photodynamic therapy 
ROS  Reactive oxygen species 
VCur  V(IV)-curcumin-bipyridine complex 
PBS  Phosphate buffered saline 
NF-κB  Nuclear factor kappa-light-chain-enhancer of activated Bcells 
Bcl2   B-cell lymphoma 2 
BclXL  B-cell lymphoma-extra large 
COX-2  Cyclooxygenase-2 
DOTAP  N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium 
EPC  Egg L-α-phosphatidylcholine 
MCLPs  Magnetic cationic liposomes 
CA  Citric acid 
MNPs  Magnetite (Fe3O4-CA) colloidal magnetic NPs 
EMCLPs Empty magnetic cationic liposomes 
VCMCLPs VCur-loaded magnetic cationic liposomes 
MeOH  Methanol 
EtOH  Ethanol 
CT  Calf thymus 
DMSO  Dimethyl sulfoxide 
FT-IR  Fourier Transform-Infrared spectroscopy 
XRD  X-ray diffraction 
HRTEM  High resolution transmission electron microscopy 
TEM  Transmission electron microscopy 
XPS  X-ray photoelectron spectroscopy 
SEM  Scanning electron microscopy 
EDX  Energy dispersive X-ray 
DLS  Dynamic Light Scattering 
TGA  Thermogravimetric Analysis 
FAAS  Flame atomic absorption spectrophotometry 
HPLC  High Performance Liquid Chromatography 
DAD  Diode array detector 
UV  UV–Visible 
Tt  Main phase transition temperature 
PTFE  Polytetrafluoroethylene 
SD  Standard deviation 
MLVs  Multilamellar vesicles 
SUVs  Small unilamellar vesicles 
ABS  Absorbance 
CD  Circular dichroism 
Tm  Melting temperature 
EB  Ethidium bromide 
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